pipette
ESEspañol

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer

Maurice Pérol, Tatsuya Yoshida, Myung-Ju Ahn, Carl Michael Gay, Martin Schüler, Haifeng Liu, Ahmet Sezer, Ahmet Erkan Bilici, Ippokratis Korantzis, Sun Min Lim, Kohei Otsubo, Óscar Juan, Yuanbin Chen, Gustavo Schvartsman, Haiyong Wang, Anne‐Marie C. Dingemans, Jeffrey Melson Clarke, Aakash P. Desai, Miguel Marigil, Yuqi Chen, Bazle Abidi, Jessie Wang, Jacob M. Sands

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsTarlatamab–durvalumab maintenance therapy resulted in significantly longer overall survival and progression-free survival than durvalumab alone among patients with extensive-stage small-cell lung cancer.

Appeared: Monday, October 26. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2609482